LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

546.92 1

Buy Sell

Overview

Share price change

24h

Current

Min

537.96

Max

564.53

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-75M -114M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+0.21% upside

Market Stats
By TradingEconomics
Market Cap	3.4B 13B
Previous open	545.92
Previous close	546.92

News Sentiment

By Acuity

70%

30%

345 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 lis 2025, 22:42 UTC

Market Talk

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 lis 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

21 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 lis 2025, 21:47 UTC

Market Talk

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 lis 2025, 21:43 UTC

Market Talk

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 lis 2025, 20:18 UTC

Market Talk

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 lis 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 lis 2025, 19:48 UTC

Market Talk

Precious Metals Fall for the Week -- Market Talk

21 lis 2025, 19:44 UTC

Earnings

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 lis 2025, 19:37 UTC

Market Talk

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 lis 2025, 19:27 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

21 lis 2025, 19:27 UTC

Market Talk

Earnings

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 lis 2025, 19:20 UTC

Market Talk

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 lis 2025, 18:44 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 lis 2025, 18:37 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 lis 2025, 18:34 UTC

Market Talk

Earnings

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 lis 2025, 18:28 UTC

Earnings

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 lis 2025, 18:03 UTC

Market Talk

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 lis 2025, 17:24 UTC

Market Talk

Global Equities Roundup: Market Talk

21 lis 2025, 17:24 UTC

Market Talk

Intuit Seen on Path to Increase Growth -- Market Talk

21 lis 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 lis 2025, 17:05 UTC

Market Talk

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 lis 2025, 16:56 UTC

Market Talk

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 lis 2025, 16:47 UTC

Market Talk

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 lis 2025, 16:35 UTC

Acquisitions, Mergers, Takeovers

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 lis 2025, 16:09 UTC

Earnings

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 lis 2025, 15:59 UTC

Market Talk

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

21 lis 2025, 15:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 lis 2025, 15:23 UTC

Market Talk

Bank of Canada Not Expected to Be Swayed by Canadian Retail Trade Data -- Market Talk

21 lis 2025, 15:17 UTC

Market Talk

Canadian Consumer Spending Softening, But Could Be Worse -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

0.21% upside

12 Months Forecast

Average 543.25 USD 0.21%

High 650 USD

Low 392 USD

Based on 13 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

345 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.